Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study

ObjectiveTo evaluate the efficacy and safety of sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma (HCC) to provide a more effective first-line treatment for patients with advanced HCC.MethodsThis open-label, prospective, phase II study incl...

Full description

Bibliographic Details
Main Authors: Dailong Li, Lu Xu, Jinxing Ji, Dan Bao, Juan Hu, Ying Qian, Yinjie Zhou, Zhuo Chen, Daojun Li, Xiaopeng Li, Xiaoling Zhang, Hao Wang, Changjun Yi, Menglu Shi, Yaqi Pang, Siqi Liu, Xinhua Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
apatinib
capecitabine
first-line treatment
hepatocellular carcinoma
immune checkpoint inhibitors
sintilimab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.944062/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.944062/full

Similar Items